Filtered By:
Drug: Simvastatin

This page shows you your search results in order of date. This is page number 6.

Order by Relevance | Date

Total 142 results found since Jan 2013.

Statins for children with familial hypercholesterolemia.
CONCLUSIONS: Statin treatment is an effective lipid-lowering therapy in children with familial hypercholesterolemia. Few or no safety issues were identified. Statin treatment seems to be safe in the short term, but long-term safety remains unknown. Children treated with statins should be carefully monitored and followed up by their pediatricians and their care transferred to an adult lipidologist once they reach 18 years of age. Large long-term randomized controlled trials are needed to establish the long-term safety issues of statins. PMID: 31696945 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - November 6, 2019 Category: General Medicine Authors: Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Tonstad S, Wiegman A, Drogari E, Ramaswami U Tags: Cochrane Database Syst Rev Source Type: research

Marked Effect Of Slco1B1 Genotype On Atorvastatin Plasma Concentrations In Statin Tolerant Cardiology Outpatients
Background and Aims: Higher plasma statin concentrations increase the concentration of statin in muscle, thereby increasing the risk of statin related myotoxicity (SRM), including myopathy and rhabdomyolysis. OATP1B1, encoded by the SLCO1B1 gene, mediates hepatic uptake from portal blood. The association of rs4149056 single-nucleotide polymorphism in SLCO1B1 with simvastatin-induced myopathy is well-established but it is less clear whether this genetic variant is a useful predictor of plasama concentrations and risk of SRM with atorvastatin, the most widely prescribed high-potency statin.
Source: Atherosclerosis - August 4, 2019 Category: Cardiology Authors: E. Robinson, D. Neely, S. Pattman, L. Boxshall, B. Nur Salwani, F. Kamali, N. Brown Tags: Posters 26 - 29 May, 2019 Source Type: research

Safety of statin drugs in patients with dyslipidemia and stable systemic autoimmune myopathies
AbstractRecent studies have shown a high prevalence of dyslipidemia in patients with systemic autoimmune myopathies (SAM). However, little is known about the safety of the use of statins in these patients, and this gap in research motivated the accomplishment of the present study. In a retrospective cohort study conducted from 2004 to 2018, 250 patients with SAM were evaluated, and 24 patients had stable forms of SAM (16 dermatomyositis, 1 polymyositis and 7 antisynthetase syndrome) but had dyslipidemia and had received statins. Patients with clinically amyopathic dermatomyositis, immune-mediated necrotizing myopathy, derm...
Source: Rheumatology International - December 5, 2018 Category: Rheumatology Source Type: research

The Association between Genetic Polymorphisms and Simvastatin-Induced Myopathy: A Narrative Synthesis of Evidence
Conclusion SLCO1B1 genotype is a useful biomarker for predicting an increased risk of simvastatin-induced myopathy. [...] © Georg Thieme Verlag KG Stuttgart · New YorkArticle in Thieme eJournals: Table of contents  |  Abstract  |  Full text
Source: Drug Research - September 7, 2018 Category: Drugs & Pharmacology Authors: Li, Xingang Sun, Shusen Xu, Xiaowei Zhao, Zhigang Li, Wei Tags: Original Article Source Type: research

Simvastatin-related myopathy in shift workers: a report of two cases
Journal Name: Drug Metabolism and Personalized Therapy Issue: Ahead of print
Source: Drug Metabolism and Personalized Therapy - August 12, 2018 Category: Drugs & Pharmacology Source Type: research

Assessment of the Risk of Rhabdomyolysis and Myopathy During Concomitant Treatment with Ticagrelor and Statins
AbstractThe introduction of ticagrelor, one of the first directly-acting oral antiplatelet drugs, provided new possibilities in the prevention of thrombotic events in patients with acute coronary syndromes (ACS). Current guidelines recommend ticagrelor in dual antiplatelet therapy with aspirin over clopidogrel for prevention of stent thrombosis in patients with ACS. Moreover, in the management of ACS, lipid-lowering treatment with high-intensity statin therapy is advised for secondary prevention of cardiovascular events over the long term. Despite the apparent advantages of combined antiplatelet and lipid-lowering treatmen...
Source: Drugs - July 12, 2018 Category: Drugs & Pharmacology Source Type: research

Statin-induced myopathy SLCO1B1 521T   >  C is associated with prediabetes, high body mass index and normal lipid profile in Emirati population
Statin-induced myopathy has been linked to the C allele of a single nucleotide polymorphism (SNP) (rs4149056) of SLCO1B1 gene. This effect is more significant, but not restricted to simvastatin. Many studies have included European, American, African and Southeast Asian ancestries, but few were carried out on Middle Eastern population.
Source: Diabetes Research and Clinical Practice - March 10, 2018 Category: Endocrinology Authors: Maha Saber-Ayad, Shaista Manzoor, Ahmed El-Serafi, Ibrahim Mahmoud, Salah Abusnana, Nabil Sulaiman Source Type: research

Statin-induced myopathy SLCO1B1 521T > C is associated with Prediabetes, high Body mass index and normal lipid profile in Emirati Population
Statin-induced myopathy has been linked to the C allele of a single nucleotide polymorphism (SNP) (rs4149056) of SLCO1B1 gene. This effect is more significant, but not restricted to simvastatin. Many studies have included European, American, African and Southeast Asian ancestries, but few were carried out on Middle Eastern population.
Source: Diabetes Research and Clinical Practice - March 10, 2018 Category: Endocrinology Authors: Maha Saber-Ayad, Shaista Manzoor, Ahmed El-Serafy, Ibrahim Mahmoud, Salah Abusnana, Nabil Sulaiman Source Type: research

Effects of a series of acidic drugs on L-lactic acid transport by the monocarboxylate transporters MCT1 and MCT4.
CONCLUSION: This inhibition may cause an accumulation of intracellular L-lactic acid leading to acidification and muscular disorders. PMID: 29521223 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Biotechnology - March 7, 2018 Category: Biotechnology Authors: Leung YH, Belanger F, Lu J, Turgeon J, Michaud V Tags: Curr Pharm Biotechnol Source Type: research

Comparative impact of systemic delivery of atorvastatin, simvastatin, and lovastatin on bone mineral density of the ovariectomized rats
ConclusionsIt was concluded that the lovastatin and simvastatin efficiently ameliorated the OVX-induced osteoporosis. Moreover, the simvastatin-treated animals showed more resemblance to the normal group in terms of BMD, expression of osteogenic genes, serum biochemical parameters, histomorphometric findings, and biomechanical performance with no significant side-effects.
Source: Endocrine - January 25, 2018 Category: Endocrinology Source Type: research

Lipid-lowering agent-triggered dermatomyositis and polymyositis: a case series and literature review
AbstractLipid-lowering agent-triggered dermatomyositis (DM) or polymyositis (PM) is a rare event. Therefore, the aim of the present study was to describe a series of such cases. A retrospective cohort study of 5 DM and 4 PM cases triggered by prior exposure to lipid-lowering agents between 2001 and 2017 was carried out. All patients, except for two cases, had muscle biopsy compatible with inflammatory myopathy and no serum autoantibodies positive for anti-SRP or anti-HMGCoAR. Median age of the patients at time of diagnosis was 68  years. Seven patients had previously taken simvastatin 20 mg/day (exposure period from 2 d...
Source: Rheumatology International - October 12, 2017 Category: Rheumatology Source Type: research

Statins for children with familial hypercholesterolemia.
CONCLUSIONS: Statin treatment is an effective lipid-lowering therapy in children with familial hypercholesterolemia. No significant safety issues were identified. Statin treatment seems to be safe in the short term, but long-term safety remains unknown. Children treated with statins should be carefully monitored and followed up by their pediatricians and their care transferred to an adult lipidologist once they reach 18 years of age. Large long-term randomized controlled trials are needed to establish the long-term safety issues of statins. PMID: 28685504 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - July 7, 2017 Category: General Medicine Authors: Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Tonstad S, Wiegman A, Drogari E, Ramaswami U Tags: Cochrane Database Syst Rev Source Type: research

10-year trends in statin utilization in Taiwan: a retrospective study using Taiwans National Health Insurance Research Database
Conclusion Atorvastatin was the most commonly used statin in Taiwan during 2002–2011. While patients with history of CVD were more likely to be prescribed higher intensity statins compared with those without, this difference was not found comparing those with and without diabetes.
Source: BMJ Open - May 17, 2017 Category: General Medicine Authors: Hsieh, H.-C., Hsu, J. C., Lu, C. Y. Tags: Open access, Evidence based practice Research Source Type: research

Impairment of Energy-Dependent Processes in the Muscle Tissue as a Pathogenetic Mechanism of Statin-Induced Myopathy
Administration of simvastatin was followed by a decrease in activities of superoxide dismutase and cytochrome oxidase in rat mitochondria, which attested to dysfunction of the respiratory chain. The decrease in total ATPase and Ca2+-ATPase activities in muscle tissue homogenates reflected impaired transport of active cations essential for muscle contraction. We conclude that abnormal relationships in the system of energy synthetic and energy-dependent processes in myocytes serve as the molecular basis for the formation of statin-induced degenerative changes.
Source: Bulletin of Experimental Biology and Medicine - February 26, 2017 Category: Biology Source Type: research